Loading...
Header Logo
Keywords
Last Name
Institution

CHADI CALARGE

TitleAssociate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Psychiatry & Behavioral Sciences
DivisionPsychiatry & Behavioral Sciences
AddressOne Baylor Plaza
Houston TX 77030
vCardDownload vCard
    Other Positions
    TitleAssociate Professor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Pediatrics
    DivisionPediatrics-Psychology


    Collapse Research 
    Collapse research activities and funding
    R21MH080968     (CALARGE, CHADI A.)Aug 1, 2008 - Feb 28, 2012
    NIH/NIMH
    Long-Term Safety and Genetic Risk Factors of Risperdone Treatment in Youth
    Role: Principal Investigator

    K23MH085005     (CALARGE, CHADI A.)Mar 1, 2009 - Feb 28, 2015
    NIH/NIMH
    Counteracting Risperidone-Induced Hyperprolactinemia in Youths
    Role: Principal Investigator

    R01MH090072     (CALARGE, CHADI A.)Jul 15, 2010 - Jun 30, 2015
    NIH/NIMH
    Serotonin Reuptake Inhibitors and Bone Mineralization in Adolescents
    Role: Principal Investigator

    R21HD097776     (CALARGE, CHADI A.)Jan 1, 2019 - Dec 31, 2020
    NIH/NICHD
    Examining SSRI-Induced Disruption of Pubertal Growth Spurt
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Calarge CA, Devaraj S, Shulman RJ. Gut permeability and depressive symptom severity in unmedicated adolescents. J Affect Disord. 2019 03 01; 246:586-594. PMID: 30605877.
      View in: PubMed
    2. Gillentine MA, Lozoya R, Yin J, Grochowski CM, White JJ, Schaaf CP, Calarge CA. CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders. J Affect Disord. 2018 10 15; 239:247-252. PMID: 30029151.
      View in: PubMed
    3. Calarge CA, Mills JA, Karaviti L, Teixeira AL, Zemel BS, Garcia JM. Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys. J Pediatr. 2018 10; 201:245-251. PMID: 29958671.
      View in: PubMed
    4. Calarge CA, Mills JA, Ziegler EE, Schlechte JA. Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. J Child Adolesc Psychopharmacol. 2018 Mar; 28(2):145-150. PMID: 29112461.
      View in: PubMed
    5. Gandy K, Kim S, Sharp C, Dindo L, Maletic-Savatic M, Calarge C. Pattern Separation: A Potential Marker of Impaired Hippocampal Adult Neurogenesis in Major Depressive Disorder. Front Neurosci. 2017; 11:571. PMID: 29123464.
      View in: PubMed
    6. Calarge CA, Mills JA, Janz KF, Burns TL, Schlechte JA, Coryell WH, Zemel BS. The Effect of Depression, Generalized Anxiety, and Selective Serotonin Reuptake Inhibitors on Change in Bone Metabolism in Adolescents and Emerging Adults. J Bone Miner Res. 2017 Dec; 32(12):2367-2374. PMID: 28815738.
      View in: PubMed
    7. Gillentine MA, White JJ, Grochowski CM, Lupski JR, Schaaf CP, Calarge CA. CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents. J Child Adolesc Psychopharmacol. 2017 Dec; 27(10):908-915. PMID: 28817303.
      View in: PubMed
    8. Dindo LN, Recober A, Haddad R, Calarge CA. Comorbidity of Migraine, Major Depressive Disorder, and Generalized Anxiety Disorder in Adolescents and Young Adults. Int J Behav Med. 2017 08; 24(4):528-534. PMID: 28032323.
      View in: PubMed
    9. Coryell WH, Langbehn DR, Norris AW, Yao JR, Dindo LN, Calarge CA. Polyunsaturated fatty acid composition and childhood adversity: Independent correlates of depressive symptom persistence. Psychiatry Res. 2017 10; 256:305-311. PMID: 28666200.
      View in: PubMed
    10. Calarge CA, Mills JA, Janz KF, Burns TL, Coryell WH, Zemel BS. Body Composition in Adolescents During Treatment With Selective Serotonin Reuptake Inhibitors. Pediatrics. 2017 Jul; 140(1). PMID: 28759400.
      View in: PubMed
    11. Calarge CA, Schlechte JA. Bone Mass in Boys with Autism Spectrum Disorder. J Autism Dev Disord. 2017 06; 47(6):1749-1755. PMID: 28342168.
      View in: PubMed
    12. Deumic E, Butcher BD, Clayton AD, Dindo LN, Burns TL, Calarge CA. Sexual Functioning in Adolescents With Major Depressive Disorder. J Clin Psychiatry. 2016 07; 77(7):957-62. PMID: 27464316.
      View in: PubMed
    13. Coryell W, Yolken R, Butcher B, Burns T, Dindo L, Schlechte J, Calarge C. Toxoplasmosis Titers and past Suicide Attempts Among Older Adolescents Initiating SSRI Treatment. Arch Suicide Res. 2016 Oct-Dec; 20(4):605-13. PMID: 27045220.
      View in: PubMed
    14. Calarge CA, Murry DJ, Ziegler EE, Arnold LE. Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. J Child Adolesc Psychopharmacol. 2016 06; 26(5):471-7. PMID: 26894929.
      View in: PubMed
    15. Coryell WH, Butcher BD, Burns TL, Dindo LN, Schlechte JA, Calarge CA. Fat distribution and major depressive disorder in late adolescence. J Clin Psychiatry. 2016 Jan; 77(1):84-9. PMID: 26580857.
      View in: PubMed
    16. Fiedorowicz JG, Andersen LE, Persons JE, Calarge C. Rapid adipose deposition with mood disorders. Ann Clin Psychiatry. 2015 Nov; 27(4):283-8. PMID: 26554369; PMCID: PMC4696501 [Available on 11/01/16].
    17. Calarge CA, Ziegler EE, Del Castillo N, Aman M, McDougle CJ, Scahill L, McCracken JT, Arnold LE. Iron homeostasis during risperidone treatment in children and adolescents. J Clin Psychiatry. 2015 Nov; 76(11):1500-5. PMID: 26301448.
      View in: PubMed
    18. Bahr SM, Tyler BC, Wooldridge N, Butcher BD, Burns TL, Teesch LM, Oltman CL, Azcarate-Peril MA, Kirby JR, Calarge CA. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 2015 Oct 06; 5:e652. PMID: 26440540; PMCID: PMC4930121.
    19. Saha PK, Liu Y, Chen C, Jin D, Letuchy EM, Xu Z, Amelon RE, Burns TL, Torner JC, Levy SM, Calarge CA. Characterization of trabecular bone plate-rod microarchitecture using multirow detector CT and the tensor scale: Algorithms, validation, and applications to pilot human studies. Med Phys. 2015 Sep; 42(9):5410-25. PMID: 26328990.
      View in: PubMed
    20. Calarge CA, Burns TL, Schlechte JA, Zemel BS. Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. J Clin Psychiatry. 2015 May; 76(5):607-13. PMID: 26035190.
      View in: PubMed
    21. Calarge CA, Schlechte JA, Burns TL, Zemel BS. The effect of psychostimulants on skeletal health in boys co-treated with risperidone. J Pediatr. 2015 Jun; 166(6):1449-54.e1. PMID: 25863660; PMCID: PMC4446198.
    22. Calarge CA, Butcher BD, Burns TL, Coryell WH, Schlechte JA, Zemel BS. Major depressive disorder and bone mass in adolescents and young adults. J Bone Miner Res. 2014 Oct; 29(10):2230-7. PMID: 24723424.
      View in: PubMed
    23. Calarge CA, Nicol G, Schlechte JA, Burns TL. Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. J Child Adolesc Psychopharmacol. 2014 Apr; 24(3):120-9. PMID: 24725198; PMCID: PMC3993060.
    24. Engelstad HJ, Roghair RD, Calarge CA, Colaizy TT, Stuart S, Haskell SE. Perinatal outcomes of pregnancies complicated by maternal depression with or without selective serotonin reuptake inhibitor therapy. Neonatology. 2014; 105(2):149-54. PMID: 24356332; PMCID: PMC4054700.
    25. Calarge CA, Ivins SD, Motyl KJ, Shibli-Rahhal AA, Bliziotes MM, Schlechte JA. Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents. Ther Adv Psychopharmacol. 2013 Oct; 3(5):278-93. PMID: 24167704; PMCID: PMC3805387.
    26. Del Castillo N, Zimmerman M B, Tyler B, Ellingrod VL, Calarge C. 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment. Clin Pharmacol Biopharm. 2013 Jun 29; 2(2):110. PMID: 24772381.
      View in: PubMed
    27. Safer DJ, Calarge CA, Safer AM. Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013 May; 23(4):282-9. PMID: 23647135; PMCID: PMC3657283.
    28. Calarge CA, Ziegler EE. Iron deficiency in pediatric patients in long-term risperidone treatment. J Child Adolesc Psychopharmacol. 2013 Mar; 23(2):101-9. PMID: 23480322; PMCID: PMC3609616.
    29. Calarge CA, Xie D, Fiedorowicz JG, Burns TL, Haynes WG. Rate of weight gain and cardiometabolic abnormalities in children and adolescents. J Pediatr. 2012 Dec; 161(6):1010-5. PMID: 22738944; PMCID: PMC3461238.
    30. Calarge CA, Nicol G, Xie D, Zimmerman B. Correlates of weight gain during long-term risperidone treatment in children and adolescents. Child Adolesc Psychiatry Ment Health. 2012 May 29; 6(1):21. PMID: 22643087; PMCID: PMC3489823.
    31. Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG. Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev. 2012 Feb 01; 8(1):25-36. PMID: 22712004.
      View in: PubMed
    32. Calarge CA, Ellingrod VL, Zimmerman B, Bliziotes MM, Schlechte JA. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry. 2011 Dec; 72(12):1685-90. PMID: 22244026; PMCID: PMC3653135.
    33. Kuperman S, Calarge C, Kolar A, Holman T, Barnett M, Perry P. An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder. Ann Clin Psychiatry. 2011 Nov; 23(4):270-6. PMID: 22073384.
      View in: PubMed
    34. Calarge CA, Miller del D. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol. 2011 Apr; 21(2):163-9. PMID: 21486167; PMCID: PMC3080754.
    35. Calarge C, Farmer C, DiSilvestro R, Arnold LE. Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2010 Dec; 20(6):495-502. PMID: 21186968; PMCID: PMC3003494.
    36. Turner CA, Xie D, Zimmerman BM, Calarge CA. Iron status in toddlerhood predicts sensitivity to psychostimulants in children. J Atten Disord. 2012 May; 16(4):295-303. PMID: 20978274; PMCID: PMC3556512.
    37. Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010 Mar; 71(3):338-47. PMID: 20331935; PMCID: PMC2845988.
    38. Calarge CA, Ellingrod VL, Zimmerman B, Acion L, Sivitz WI, Schlechte JA. Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet. 2009 Dec; 19(6):320-7. PMID: 19873684; PMCID: PMC2919234.
    39. Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May; 19(5):373-82. PMID: 19339912; PMCID: PMC2699901.
    40. Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009 Apr; 19(2):101-9. PMID: 19364288; PMCID: PMC2715008.
    41. Andreasen NC, Calarge CA, Calage CA, O'Leary DS. Theory of mind and schizophrenia: a positron emission tomography study of medication-free patients. Schizophr Bull. 2008 Jul; 34(4):708-19. PMID: 18559406; PMCID: PMC2632446.
    42. Calarge C, Kuperman S. Fluoxetine for depression relapse prevention. J Am Acad Child Adolesc Psychiatry. 2005 Oct; 44(10):966-7; author reply 967-8. PMID: 16175095.
      View in: PubMed
    43. Calarge CA, Crowe RR. Electroconvulsive therapy in myasthenia gravis. Ann Clin Psychiatry. 2004 Oct-Dec; 16(4):225-7. PMID: 15702571.
      View in: PubMed
    44. Calarge CA, Crowe RR, Gergis SD, Arndt S, From RP. The comparative effects of sevoflurane and methohexital for electroconvulsive therapy. J ECT. 2003 Dec; 19(4):221-5. PMID: 14657775.
      View in: PubMed
    45. Calarge C, Andreasen NC, O'Leary DS. Visualizing how one brain understands another: a PET study of theory of mind. Am J Psychiatry. 2003 Nov; 160(11):1954-64. PMID: 14594741.
      View in: PubMed
    CALARGE's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description